Quick answer: Irritable bowel syndrome affects 10–15% of the global population, making it the most common gastrointestinal diagnosis worldwide — yet the standard treatment (fiber, antispasmodics, low-FODMAP diet) addresses symptoms without identifying root causes. A landmark 2000 study by Pimentel (American Journal of Gastroenterology) found that 78% of IBS patients tested positive for small intestinal bacterial overgrowth (SIBO) on lactulose breath testing, and antibiotic treatment (rifaximin) normalized breath tests and improved IBS symptoms in 48% — the first evidence that a significant proportion of “IBS” was actually untreated bacterial infection explaining gut motility and permeability dysfunction.
Small Intestinal Bacterial Overgrowth (SIBO): Mechanisms, Testing, and Treatment
The small intestine normally contains fewer than 10³ organisms per milliliter of luminal content — maintained by gastric acid (kills most ingested bacteria), the migrating motor complex (MMC — the “sweeping” peristaltic waves during fasting that clear bacteria distally), the ileocecal valve (preventing colonic bacteria backflow), and secretory IgA (immune surveillance). SIBO develops when these defense mechanisms are compromised — producing 10⁵–10⁹ organisms/mL in the small intestine, where they ferment carbohydrates into gas (hydrogen, methane, hydrogen sulfide), compete for nutrients, deconjugate bile acids (causing fat malabsorption and diarrhea), and trigger intestinal permeability and immune activation.
Three distinct SIBO types have different clinical presentations and treatment implications: Hydrogen-dominant SIBO (most common — 50–65% of cases) produces excess hydrogen gas from hydrogen-producing bacteria (Escherichia, Klebsiella, Enterobacter) fermenting carbohydrates. Clinical presentation: diarrhea-predominant, bloating immediately after eating, loose stools. Methane-dominant SIBO (also called intestinal methanogen overgrowth, IMO — 25–35% of cases) involves archaea (Methanobrevibacter smithii) converting hydrogen into methane gas. Methane directly reduces intestinal motility — methane exposure causes colonic muscle to contract tonically (Pimentel 2006, Digestive Diseases and Sciences). Clinical presentation: constipation-predominant, extreme bloating, weight gain (methane impairs gut transit allowing greater caloric extraction from food). Hydrogen sulfide-dominant SIBO (most recently recognized — 5–15% of cases, previously unmeasurable) involves sulfate-reducing bacteria (Desulfovibrio, Bilophila) producing H₂S — a potent intestinal permeability disruptor, genotoxin, and cytotoxin. Clinical presentation: diarrhea, urgency, sulfur/rotten egg odor, and paradoxical false-negative hydrogen/methane breath tests (H₂S doesn’t register on standard 2-gas testing).
Breath testing — measuring exhaled hydrogen and methane after lactulose (or glucose) challenge — is the standard non-invasive SIBO diagnostic. The 3-gas TRIO Smart breath test (also measuring hydrogen sulfide) provides the most complete picture. Glucose breath test has higher specificity (90%+) but lower sensitivity for SIBO extending beyond the duodenum; lactulose breath test has higher sensitivity but lower specificity due to colonic fermentation confounding. Specific IBS-Smart serology (CdtB and vinculin antibodies — anti-vinculin antibody reflects post-infectious IBS from damage to intestinal pace-making cells following food poisoning) identifies the post-infectious IBS-SIBO subset. The root causes of SIBO that must be identified and corrected to prevent recurrence include: low gastric acid (proton pump inhibitor use, H. pylori, aging), impaired MMC (opioid use, hypothyroidism, diabetes, previous abdominal surgery creating adhesions), ileocecal valve dysfunction, and immune deficiency (IgA deficiency).
SIBO treatment: Rifaximin 550 mg three times daily for 14 days is the gold-standard antibiotic for hydrogen SIBO (Pimentel 2011 TARGET 1 and 2 RCTs — 40.7% vs. 22.1% response for IBS-D). For methane IMO, neomycin 500 mg twice daily combined with rifaximin (Pimentel 2006 — 85% vs. 33% normalization). Herbal antimicrobial regimens (Allimed/allicin concentrate, oregano oil, berberine, neem, and bismuth subcitrate combinations) achieve equivalent SIBO eradication rates to rifaximin in a 4-week protocol — Chedid 2014 (Global Advances in Health and Medicine) found herbal therapy eradicated SIBO in 46% versus 34% for rifaximin (non-inferior). Post-treatment motility support (prokinetics) is essential to prevent recurrence: low-dose naltrexone 1–4.5 mg, ginger 1,000 mg, 5-HTP 50 mg, or erythromycin 50 mg at bedtime all stimulate the MMC. Probiotics are controversial during active SIBO treatment — Lactobacillus rhamnosus and Bifidobacterium strains are introduced after eradication, while soil-based organisms (Bacillus subtilis, Bacillus licheniformis — Pillows et al. 2017) may have benefits during treatment due to their different fermentation characteristics.
GERD and LPR: Low Stomach Acid, Hiatal Hernia, and H. pylori — Not Acid Overproduction
The conventional model of GERD attributes it to excessive acid production requiring suppression — a paradigm now challenged by extensive functional medicine research and the clinical observation that millions of patients remain symptomatic on proton pump inhibitors (PPIs) while developing serious nutrient deficiencies and microbiome disruption from long-term acid suppression. A more accurate functional model recognizes that reflux symptoms can result from either excessive OR insufficient gastric acid — and that the majority of GERD patients in functional medicine practice have low or normal acid with impaired lower esophageal sphincter (LES) tone as the primary mechanism.
Jonathan Wright, MD — a pioneer of integrative gastroenterology — observed in clinical practice that hypochlorhydria (low stomach acid) produces identical symptoms to hyperchlorhydria: heartburn, belching, bloating, and regurgitation. The mechanism: insufficient acid → impaired protein digestion → undigested food fermenting in the stomach → gas production increasing intragastric pressure → LES forced open → acid gas reflux (even at physiologically low pH, refluxed acid burns the esophagus). Additionally, low acid → SIBO (gastric acid kills most ingested bacteria; PPIs dramatically increase SIBO risk — Jacobs 2013 found PPI use increased SIBO odds ratio 7.59) → SIBO gas production worsens reflux symptoms. PPI use for more than 1 year is associated with: 65% increased hip fracture risk (Yang 2006, JAMA), significant Clostridioides difficile risk (Deshpande 2012 meta-analysis), magnesium deficiency (FDA warning 2011), B12 deficiency, and significant gut microbiome disruption.
H. pylori infects approximately 44% of the world’s population and approximately 35% of Americans — the most common chronic bacterial infection in humans. H. pylori colonizes the gastric antrum, suppresses gastric acid production (through urease activity producing ammonia that neutralizes acid), and progressively leads to atrophic gastritis and pernicious anemia in a significant proportion of chronically infected patients. While H. pylori eradication is standard for peptic ulcer disease, many functional practitioners argue that eradication should be offered to all H. pylori-positive patients given its relationship to B12 deficiency, iron malabsorption, SIBO, and gastric cancer risk. Triple therapy (PPI + amoxicillin + clarithromycin) now has only 70–80% eradication rates due to clarithromycin resistance — bismuth quadruple therapy or sequential therapy achieves 90%+ eradication. Functional adjuncts: mastic gum 1,000 mg twice daily (Huwez 1998 — H. pylori eradication with mastic gum monotherapy in RCT); broccoli sprout extract (sulforaphane) significantly reduces H. pylori density and urease activity in RCTs (Yanaka 2009, Cancer Prevention Research).
Functional GERD treatment: identify and treat SIBO (most important single intervention); H. pylori eradication if positive; weight loss (LES tone is mechanically impaired by obesity — each BMI unit increase correlates with increased GERD risk); food trigger identification (high-fat meals, coffee, alcohol, mint, chocolate, and citrus relax LES); elimination diet for non-acid reflux (food sensitivities drive LPR through eosinophilic esophagitis in a significant minority); elevate head of bed 4–6 inches; avoid eating within 3 hours of bed; HCl + pepsin challenge (under physician supervision) to identify hypochlorhydria — if betaine HCl 650 mg with a protein meal improves rather than worsens symptoms, hypochlorhydria is likely; deglycyrrhizinated licorice (DGL) 380 mg chewable before meals soothes and protects esophageal/gastric mucosa.
IBS: Post-Infectious Mechanisms, the Low-FODMAP Diet, and Gut-Brain Axis Dysregulation
Irritable bowel syndrome (IBS) is a diagnosis of exclusion defined by the Rome IV criteria: recurrent abdominal pain averaging at least 1 day/week for 3+ months, associated with defecation changes or altered stool form. Functional medicine recognizes IBS as a heterogeneous syndrome with multiple distinct root causes requiring individualized identification rather than one-size-fits-all management.
Post-infectious IBS (PI-IBS) accounts for approximately 10–15% of new IBS cases and arises after acute gastroenteritis — most commonly Campylobacter, Salmonella, Shigella, or Giardia. Thabane 2007 (Gut) found that 8.9% of patients developed IBS in the year following acute gastroenteritis, with persistent risk up to 8 years. The CdtB toxin from Campylobacter and other pathogens produces antibodies (anti-CdtB, anti-vinculin) that cross-react with vinculin in intestinal pacemaking cells (interstitial cells of Cajal), impairing MMC function and creating the motility dysfunction underlying PI-IBS. IBS-Smart serology testing (anti-CdtB and anti-vinculin antibodies) identifies this mechanism — with anti-vinculin antibody present in 44% of IBS patients versus 7% of healthy controls. This subgroup responds best to low-dose naltrexone (prokinetic + anti-neuroinflammatory dual action), rifaximin, and motility support.
The low-FODMAP diet (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) has the strongest RCT evidence for IBS symptom reduction — Halmos 2014 (Gastroenterology) found 70% of IBS patients reported adequate relief on low-FODMAP diet versus 22% on control diet. The mechanism is gas reduction in the proximal colon and small intestine, reducing abdominal distension and pain. However, low-FODMAP is a SYMPTOM MANAGEMENT tool, not a root-cause treatment — it reduces fermentable substrate available to bacteria but does not correct the underlying dysbiosis. Long-term low-FODMAP use reduces Bifidobacterium by 47% (Staudacher 2012, Journal of Nutrition) — potentially worsening dysbiosis and colonic barrier function over time. The functional approach uses low-FODMAP temporarily during active treatment (SIBO eradication, dysbiosis correction) then systematically reintroduces FODMAPs as gut health improves.
Gut-brain axis dysregulation in IBS operates through bidirectional pathways: stress activates CRH release, which increases intestinal permeability, alters motility, and heightens visceral sensitivity through mast cell activation in the intestinal wall. The enteric nervous system (100 million neurons) responds to stress signals by altering MMC activity, goblet cell mucus production, and epithelial barrier function — creating a positive feedback loop where gut symptoms amplify anxiety which worsens gut function. Visceral hypersensitivity — lowered pain threshold for gut stimuli — is the hallmark of IBS brain-gut interaction. CBT and gut-directed hypnotherapy are evidence-based brain-gut axis interventions: Irritable Bowel Syndrome Outcome Study (Guthrie 1991) showed gut-directed hypnotherapy produced significant improvement in 80% of treatment-refractory IBS patients.
Leaky Gut (Intestinal Permeability): The Common Root of Multiple Digestive Disorders
Increased intestinal permeability — what functional practitioners call “leaky gut” — is not merely a functional medicine concept but a well-researched physiological state with measurable biomarkers (zonulin, lactulose/mannitol ratio, intestinal fatty acid binding protein, LPS-binding protein). Fasano 2012 (Clinical Reviews in Allergy and Immunology) comprehensively documented the role of zonulin — the only known physiological regulator of tight junctions — in regulating intestinal permeability, with elevated zonulin found in celiac disease, type 1 diabetes, SIBO, inflammatory bowel disease, and multiple sclerosis. Gluten is the most potent known stimulator of zonulin release in all individuals (not only those with celiac disease) — with gliadin fragments binding CXCR3 receptors on enterocytes and triggering zonulin upregulation through an IL-8-dependent mechanism (Hollon 2015, Nutrients).
The leaky gut healing protocol has four components: Remove — dietary triggers (gluten, dairy, high-sugar foods, alcohol, NSAIDs which directly impair intestinal tight junctions — causing leaky gut measurably within hours of administration — Bjarnason 1986, Lancet), infections (H. pylori, Candida, SIBO, parasites), toxins (antibiotics, food additives like polysorbate 80 and carboxymethylcellulose that disrupt mucosal layer — Chassaing 2015, Nature). Replace — digestive capacity: betaine HCl (if hypochlorhydric), digestive enzymes, ox bile (for fat malabsorption). Repair — structural nutrients: L-glutamine 5–10 g/day (primary fuel for enterocytes; Ziegler 1988 demonstrated 30% greater intestinal permeability in TPN patients without glutamine vs. with), zinc carnosine 75–150 mg/day (Mahmood 2007, Gut — zinc carnosine reduced NSAID-induced intestinal injury by 50%; specifically repairs tight junctions), colostrum (immunoglobulins and IGF-1 directly repair intestinal epithelium), deglycyrrhizinated licorice (protects and soothes mucosal lining), aloe vera (anti-inflammatory mucosal coating). Reinoculate — microbiome: multi-strain probiotics including Bifidobacterium longum (BB536 has RCT evidence for IBS-D), L. rhamnosus GG, L. acidophilus NCFM, and Saccharomyces boulardii; prebiotic fiber (inulin, FOS, GOS — gradually increased to avoid SIBO exacerbation); fermented foods post-treatment.
Frequently Asked Questions
What is SIBO and how do I know if I have it?
SIBO (small intestinal bacterial overgrowth) occurs when bacteria colonize the small intestine in excess — producing gas (hydrogen, methane, or hydrogen sulfide) that causes bloating, distension, flatulence, and altered bowel habits. Symptoms overlap significantly with IBS, fibromyalgia, and rosacea. Diagnosis is by lactulose or glucose breath test measuring exhaled hydrogen and methane; the 3-gas TRIO Smart test also measures hydrogen sulfide. A positive test combined with symptoms warrants treatment. SIBO underlies approximately 78% of IBS cases (Pimentel 2000) and 46% of rosacea cases (Parodi 2008).
Should I stop my proton pump inhibitor?
Never stop a PPI abruptly without physician guidance — acid rebound can cause severe symptoms. However, long-term PPI use significantly increases SIBO risk (OR 7.59), hip fracture risk (65%), C. difficile risk, and causes B12, magnesium, and calcium malabsorption. The functional approach identifies WHY you need PPI (H. pylori, SIBO, hiatal hernia, food sensitivities, low LES tone) and addresses root causes — allowing gradual, supervised PPI tapering as the underlying conditions are resolved. DGL licorice and zinc carnosine can support the transition.
What is the best diet for IBS?
The low-FODMAP diet provides the best short-term symptom relief (70% response rate — Halmos 2014). However, it is a symptom management tool, not a cure — long-term use reduces Bifidobacterium by 47%. The most effective long-term approach: use low-FODMAP temporarily during SIBO treatment or dysbiosis correction, then systematically reintroduce FODMAPs. For PI-IBS (post-infectious IBS with positive anti-vinculin antibody), rifaximin + LDN + prokinetics addresses the root cause. For stress-driven IBS, gut-directed hypnotherapy and mind-body practices complement dietary changes.
What is leaky gut and can it really be healed?
Intestinal permeability (leaky gut) is a measurable physiological state in which tight junctions between intestinal epithelial cells become compromised, allowing bacterial products (LPS), undigested food proteins, and toxins to enter the bloodstream and trigger systemic inflammation. It is documented in IBS, SIBO, celiac disease, IBD, and multiple autoimmune conditions. Yes, it can be healed — the intestinal epithelium has a turnover time of 3–5 days, enabling rapid structural repair when triggers are removed and repair nutrients (L-glutamine, zinc carnosine, colostrum) are provided. Complete healing typically requires 3–6 months of comprehensive protocol adherence.
Functional gastroenterology addresses the root causes of digestive disorders that symptom-focused medicine consistently misses — SIBO underlying most IBS, hypochlorhydria driving GERD, H. pylori impairing nutrient absorption, and leaky gut connecting digestive dysfunction to systemic inflammation. At The Private Practice, we use comprehensive breath testing, stool analysis, and food sensitivity evaluation to identify and treat your specific digestive root causes. Call us at (810) 206-1402 to schedule your functional gastroenterology consultation.